AstraZeneca, Korea’s Hanmi Move To Appellate Court In Nexium Patent Dispute
This article was originally published in PharmAsia News
Executive Summary
A recent settlement agreement at the U.S. district court level does little to resolve a battle over AstraZeneca’s second best-selling drug. Saying its position is on “solid ground,” it remains unclear if Hanmi would pursue an at-risk launch if it receives final FDA approval.
You may also be interested in...
Crestor Patent Settlement Allows Actavis Generic Entry In May 2016
The agreement permits Actavis to launch its generic version of AstraZeneca’s Crestor 67 days before the patent on the cholesterol-lowering drug expires in return for paying AstraZeneca 39% of its net sales during this period; Actavis may also launch its alternative zinc salt formulation of Crestor at the same time.
At-Risk Launches: Three Cases May Determine How Damages Are Calculated
How risky are at-risk launches of generic products?
Teva Could Face Damages Of $1.2 Billion For At-Risk Launch Of Generic Protonix
A jury finds that Pfizer's patent on the proton pump inhibitor is valid; analyst Timothy Anderson estimates that without a settlement Teva's damages could top $1 billion but thinks the actual impact will be smaller.